Analysis reveals SPOP mutations and MMR/MSI status influence PD-L1 levels in prostate cancer, suggesting relevance for immunotherapy.
Our analysis identifies SPOP mutations and MMR/MSI status as cofactors in high PD-L1 expression and CD8/TIL presence in PCa, representing potential markers for selecting patients who are more likely to respond immunotherapy or to combined treatment.
No takes yet. Share an insight, caveat, or question.
Fiorentino et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: